{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:38:12Z","timestamp":1788838692452,"version":"build-2803163510"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Over the past decade, non-vitamin K antagonist oral anticoagulants have revolutionized anticoagulation therapy, offering substantial benefits over traditional vitamin K antagonists. Non-vitamin K antagonist oral anticoagulants offer reduced bleeding risks, fixed dosing without frequent monitoring, and fewer drug and dietary interactions. Their effectiveness has been demonstrated in preventing stroke in atrial fibrillation, managing venous thromboembolism, and offering new options for patients with coronary artery disease and cancer-associated thrombosis. However, challenges remain, including bleeding risks, high costs, and limited efficacy in certain patient populations. Current research is focused on addressing these limitations, with Factor XI inhibitors emerging as a promising advancement for safer anticoagulation. This review provides an overview of the clinical highlights, challenges, and future directions of anticoagulation therapy.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suae087","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:18:40Z","timestamp":1739963920000},"page":"i6-i11","source":"Crossref","is-referenced-by-count":4,"title":["Over 10 years of non-vitamin K antagonist oral anticoagulants: highlights, challenges, and future developments"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-574X","authenticated-orcid":false,"given":"Raffaele","family":"De Caterina","sequence":"first","affiliation":[{"name":"Cardio-Thoracic and Vascular Department, Pisa University Hospital and University of Pisa , Via Paradisa, 2, 56125 Pisa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1131-2755","authenticated-orcid":false,"given":"Simona","family":"Chiusolo","sequence":"additional","affiliation":[{"name":"Cardio-Thoracic and Vascular Department, Pisa University Hospital and University of Pisa , Via Paradisa, 2, 56125 Pisa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"2025021911181692800_suae087-B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2017.180","article-title":"Era of the NOACs","author":"Huynh","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"2025021911181692800_suae087-B2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2020","journal-title":"Eur Heart J"},{"key":"2025021911181692800_suae087-B3","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2025021911181692800_suae087-B4","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"2025021911181692800_suae087-B5","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2025021911181692800_suae087-B6","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC)","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2025021911181692800_suae087-B7","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1160\/TH15-09-0703","article-title":"Oral anticoagulants in coronary heart disease (section IV). Position paper of the ESC Working Group on Thrombosis - task force on anticoagulants in heart disease","volume":"115","author":"De Caterina","year":"2016","journal-title":"Thromb Haemost"},{"key":"2025021911181692800_suae087-B8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.amjmed.2021.08.026","article-title":"Non-vitamin K antagonists versus warfarin in patients with atrial fibrillation and bioprosthetic valves: a systematic review and meta-analysis","volume":"135","author":"Cardoso","year":"2022","journal-title":"Am J Med"},{"key":"2025021911181692800_suae087-B9","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1161\/CIR.0000000000001092","article-title":"Management of patients at risk for and with left ventricular thrombus: a scientific statement from the American Heart Association","volume":"146","author":"Levine","year":"2022","journal-title":"Circulation"},{"key":"2025021911181692800_suae087-B10","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3390\/jcm11071945","article-title":"A prospective study to evaluate the effectiveness of edoxaban for the resolution of left atrial thrombosis in patients with atrial fibrillation","volume":"11","author":"Patti","year":"2022","journal-title":"J Clin Med"},{"key":"2025021911181692800_suae087-B11","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/ehjcvp\/pvz069","article-title":"Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study","volume":"6","author":"Olsen","year":"2019","journal-title":"Euro Heart J - Cardiovasc Pharmacother"},{"key":"2025021911181692800_suae087-B12","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"2025021911181692800_suae087-B13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrcardio.2017.223","article-title":"Reversal agents for non-vitamin K antagonist oral anticoagulants","volume":"15","author":"Levy","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"2025021911181692800_suae087-B14","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehac464","article-title":"Factor XI inhibitors: cardiovascular perspectives","volume":"44","author":"De Caterina","year":"2023","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/27\/Supplement_1\/i6\/61968536\/suae087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/27\/Supplement_1\/i6\/61968536\/suae087.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:18:45Z","timestamp":1739963925000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/27\/Supplement_1\/i6\/8023324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":14,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2025,2,19]]},"published-print":{"date-parts":[[2025,2,19]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suae087","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2025,2]]}}}